Energetic Biotech, Teva remain focused on NERVENTRA scientific development program for multiple sclerosis Teva Pharmaceutical Sectors Ltd. In accordance with European regulations, Teva and Active Biotech intend to request a re-exam of the CHMP opinion. Teva and Active Biotech are focusing on evaluating the CHMP's review and can continue to liaise closely with the EMA in attempting to make NERVENTRA available as a new treatment option for sufferers with RRMS in European countries..The panel estimates that almost 50 MH events might occur every year in ‘standalone’ ASCs . The panel calls on each ASC to develop, evaluate, and/or revise its MH transfer plan. Dr Larach and her fellow panel people hope their guide can help ASCs to ‘attain optimal streamlined care with particular focus on the unique medical requirements of the surgical/medical patient with an MH crisis.
Alnylam announces complete outcomes from ALN-RSV01 Phase IIb trial on RSV infection Alnylam Pharmaceuticals, Inc. , a respected RNAi therapeutics company, announced today complete results from its Phase IIb trial with ALN-RSV01 for the treating respiratory syncytial virus disease in lung transplant patients.